Janssen (J&J) Expands its PTG-200 Collaboration with Protagonist for Second Generation Oral IL-23 Receptor Antagonists

 Janssen (J&J) Expands its PTG-200 Collaboration with Protagonist for Second Generation Oral IL-23 Receptor Antagonists

Janssen (J&J) Expands its PTG-200 Collaboration with Protagonist for Second Generation Oral IL-23 Receptor Antagonists

Shots:

  • Protagonist to receive $25M upfront, $1.0B as development, regulatory & commercial milestones & royalties on product sales with rights to co-detail both products. Janssen to get exclusive WW rights to develop & commercialize both candidates and will pay certain costs and milestones for advancing preclinical candidates through P-I
  • In 2017, the companies entered into an agreement to co-develop & commercialize PTG-200 for Crohn’s disease & Janssen will be responsible for its all development & commercializing activities post P-II completion
  • Protagonist’s PTG-200 is an oral gut-restricted IL-23 receptor antagonist, a targeted therapy for inflammatory bowel disease (IBD) with the expected onset of P-II study in H1’19

Click here to read full press release/ article | Ref: Protagonist | Image: My Central Jersey

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post